Impact of New Variants and Vaccines on the Course of COVID-19
NCT ID: NCT05384886
Last Updated: 2022-05-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
15967 participants
OBSERVATIONAL
2022-01-01
2022-05-19
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Case fatality rates (CFR) are an important index that helps to understand the epidemiological characteristics of an epidemic. In the data coming in 2020, COVID-19 CFR values were generally reported in the range of 0.001-0.706. However, from 2019 to 2022, there were 2 major changes that could affect the CFR of the disease. The first of these is vaccine applications, and the second is the new variants of SARS-CoV-2, which appeared first. From 2019 to 2022, it is likely that there will be a change in the mortality of COVID-19 in relation to both the vaccines administered and the new variants emerging. However, the data on this subject are not clear yet and more studies are needed.
The aim of this study is to determine whether there is a change in the mortality of COVID-19 from 2019, when it first appeared, to 2022.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
COVID-19 Breakthrough Infection in Fully Vaccinated People and in People Who Received a Booster Dose
NCT05392075
A Longitudinal Study of COVID-19 Sequelae and Immunity
NCT04411147
COVID19 Clinical Predictors and Outcome
NCT04416347
Surveillance of Individuals Following SARS-CoV-2 Infection
NCT04383444
Seroepidemiological Study of SARS-CoV-2 (COVID-19) Infection in Population Subgroups in the State of São Paulo
NCT04408014
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Case fatality rates (CFR) are an important index that helps to understand the epidemiological characteristics of an epidemic. The CFR for COVID 19 is the number of deaths in COVID-19 cases divided by the total number of people infected with COVID-19. After the emergence of the disease in 2019, the CFR figures reported for COVID-19 in 2020 began to become clear. In the data coming in 2020, COVID-19 CFR values are generally reported in the range of 0.001-0.706. However, from 2019 to 2022, there were 2 major changes that could affect the CFR of the disease. The first of these is the vaccine applications developed against COVID-19. The first vaccine studies have matured by 2020 and started to be applied widely in the world in 2021. the second is the new variants of the first emerging SARS-CoV-2. In 2021, variants started to be defined and Alpha, Beta, Delta, and Omicron variants were reported as dominance variants from time to time. From 2019 to 2022, it is likely that there will be a change in the mortality of COVID-19 in relation to both the vaccines administered and the new variants emerging. Knowing the possible changes that may occur in COVID-19 mortality may cause changes in the COVID-19 measures applied all over the world. In this way, it may be possible to reduce unnecessary health costs and direct health resources to appropriate areas.
The aim of this study is to determine whether there is a change in the mortality of COVID-19 from 2019, when it first appeared, to 2022.
In this study, patient data were obtained retrospectively in a training and research hospital COVID-19 outpatient clinic. The obtained daily number of patients in 2020, CFR rates were compared with the number of daily patients and CFR rates in 2022. In this way, it was tested whether there was a significant difference between the year 2020, when the disease first became widespread, and 2022.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group1: COVID-19 patients in 2020
All patients over the age of 18 diagnosed with COVID-19 in 2020
Polymerase chain reaction
Covid-19 genetic material detection from mouth and nose swab
Group: COVID-19 patients in 2022
All patients over the age of 18 diagnosed with COVID-19 in 2022
Polymerase chain reaction
Covid-19 genetic material detection from mouth and nose swab
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Polymerase chain reaction
Covid-19 genetic material detection from mouth and nose swab
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Clinical outcome cannot be followed
* Patients with severe trauma
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Izmir Katip Celebi University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Adnan Yamanoğlu
Assistant professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
IKCU, Atatürk Eğitim ve Araştırma Hastanesi, Acil Tıp
Izmir, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB-867
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.